Dipyridamole monotherapy in schizophrenia
Authors:
- 3 May 2011
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 218 (2) , 341-345
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Adenosine hypothesis of schizophrenia – Opportunities for pharmacotherapyNeuropharmacology, 2012
- Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trialHuman Psychopharmacology: Clinical and Experimental, 2011
- Adenosine–Dopamine Interactions in the Pathophysiology and Treatment of CNS DisordersCNS Neuroscience & Therapeutics, 2010
- The Effects of Galantamine on Psychopathology in Chronic Stable SchizophreniaClinical Neuropharmacology, 2009
- Postsynaptic Action of Brain-Derived Neurotrophic Factor Attenuates α7 Nicotinic Acetylcholine Receptor-Mediated Responses in Hippocampal InterneuronsJournal of Neuroscience, 2008
- Adenosine A2A receptors in Parkinson’s disease treatmentPurinergic Signalling, 2008
- Adenosine A2A Receptor Antagonists for Parkinson???s DiseaseDrugs & Aging, 2005
- Dipyridamole attenuates the development of iminodipropionitrile-induced dyskinetic abnormalities in ratsBrain Research Bulletin, 1995
- Mapping of a Human A2a Adenosine Receptor (ADORA2) to Chromosome 22Genomics, 1994
- Which factors affect treatment response in late paraphrenia?International Journal of Geriatric Psychiatry, 1992